$AMD

iShares MSCI USA Momentum Factor ETF (MTUM) Sells AMD and Micron

iShares MSCI USA Momentum Factor ETF (MTUM) sold shares of AMD, Micron, Intel, Cisco, and Johnson & Johnson on Wednesday, totaling $122.9 million in net outflows. The fund reduced 122 positions, with no new buys or full exits. MTUM has $20.54 billion in assets and a 0.15% expense ratio, with a year-to-date return of 28.19%.

Original reporting
Published Oct 2, 2026, 10:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 10:40 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AMD
Bearish
medium confidence
Mentioned
$AMD · $MU · $INTC · $CSCO · $JNJ · $MSCI
Relevance
4/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$AMDBearishLow
01

Why it matters

The fund's sell activity may temporarily depress the stocks it reduced, but the overall impact is limited given the modest size relative to market caps.

02

Market read

ETF position changes provide short-term trading signals for the affected stocks, though the broader market impact is limited.

03

What to watch

Potential reallocation to other high-momentum names not disclosed in the article.

Relevance 4/10Novelty 4/10Timing: same-day

Background

MTUM is a $20.5B US momentum ETF that recently executed a $122.9M net outflow, selling multiple large-cap holdings.

Company-level read

Ticker impact

$AMDBearishMedium confidence
Context

MTUM sold $7.9M of AMD shares, reducing its stake by 12,960 shares.

Expected impact

likely pressure as the market prices in the sell-off

Evidence & confidence

ETF outflow signals reduced momentum exposure, which can weigh on price in the near term.

$MUBearishMedium confidence
Context

MTUM sold $6.9M of Micron Technology shares, cutting 6,448 shares.

Expected impact

likely pressure as the market prices in the sell-off

Evidence & confidence

Large sell by a momentum fund can temporarily depress the stock.

$INTCBearishMedium confidence
Context

MTUM sold $6.0M of Intel shares, reducing its holding by 50,048 shares.

Expected impact

likely pressure as the market prices in the sell-off

Evidence & confidence

Significant share reduction by a major ETF may affect sentiment.

$CSCOBearishMedium confidence
Context

MTUM sold $4.2M of Cisco Systems shares, cutting 39,200 shares.

Expected impact

likely pressure as the market prices in the sell-off

Evidence & confidence

ETF sell activity can temporarily impact price, though magnitude is modest.

$JNJBearishMedium confidence
Context

MTUM sold $4.1M of Johnson & Johnson shares, reducing its stake by 15,376 shares.

Expected impact

likely pressure as the market prices in the sell-off

Evidence & confidence

Even defensive stocks can feel short-term impact from large ETF sell orders.

Market effects

Momentum fund trimming may slightly reduce demand for large-cap tech stocks.

U.S. equity market may see modest downward pressure in the affected holdings.

Limited to U.S. large-cap equities; no broader global effect.

Counterpoint

The sell could be a buying opportunity if the ETF's move is purely tactical.

Key entities

  • iShares MSCI USA Momentum Factor ETF

    Large U.S. momentum-focused exchange-traded fund.

Related articles

$JNJHighAI 8/10

Johnson and Johnson Stock Plunges 6% As Medical Device Sales Miss Wall Street Forecasts

Johnson & Johnson (JNJ) reported Q3 revenue of $25.4B, beating estimates, but shares fell 6% due to weak MedTech sales of $8.6B, missing forecasts. Pharmaceutical sales rose 7.7% to $16.76B. The company raised its full-year outlook and plans a potential spin-off of its orthopedics unit. According to the company, a talc settlement and deal costs of $7B impacted earnings.

$JNJMed

The Open Question Under Johnson & Johnson Stock's Price

Johnson & Johnson (JNJ) introduced new drugs, including ICOTYDE for plaque psoriasis. Management expects ICOTYDE to become a major asset, though sales figures are not yet disclosed. Bank of America raised its peak sales estimate for ICOTYDE to $4.5 billion. Innovative Medicine, J&J's drug unit, generated $60.4 billion in 2025, 64% of total revenue. J&J plans to report ICOTYDE sales in 2027.

$MUMed

Elon Musk Backs Micron’s Pricing Restraint After a 4-Day Stock Slide

Elon Musk praised Micron for reasonable memory pricing, contrasting it with rivals. Micron's stock fell 3.62% to $953.19, down 11.54% over five sessions, despite a $150 billion backlog and strong demand. Concerns about Chinese competition and potential supply increases contributed to the decline, though JPMorgan analysts remain bullish on long-term contracts.

$AMDMedAI 8/10

Fermi and AMD sign credit support deal for build-out of Project Matador campus in Amarillo, Texas

Fermi and AMD have signed a credit support deal for Fermi's Project Matador data center campus in Amarillo, Texas. AMD will act as a guarantor for Fermi's financing, with Fermi expected to provide up to 650MW of data center space. The deal includes AMD's Instinct GPUs for AI workloads. Fermi's contract with TensorWave could be worth up to $6.5 billion over 15 years. Fermi aims to build a 17GW data center campus with diverse energy sources.